Intravitreal dexamethasone implant — a new treatment for idiopathic posterior scleritis: A case report

BACKGROUND Posterior scleritis is one of the most easily missed and misdiagnosed diseases in ophthalmology.In this case we treated a patient with intravitreal dexamethasone implant that has not been extensively studied before.CASE SUMMARY A 40-year-old female patient who had anxiety,palpitation,and insomnia presented with eye pain and decreased vision in the left eye.An eye examination indicated that her visual acuity(VA)was 40/100.Her left eye presented conjunctival edema,mild exophthalmos,clear cornea,KP(-),and clear aqueous humor.In the fundus,there was a cinerous retinal protuberance.Ultrasonography showed“T-sign”and no systemic association was detected in laboratory examination.One month after injection of dexamethasone implant,the patient exhibited VA of 20/20,fundus serous retinal detachment disappeared,and intraocular pressure of both eyes was at the normal level.CONCLUSION Intravitreal injection of dexamethasone implant may be a safe and effective treatment for patients with idiopathic posterior scleritis.

An eighteen-month follow-up study on the effects of Intravitreal Dexamethasone Implant in diabetic macular edema refractory to anti-VEGF therapy

AIM： To evaluate the long-term efficacy and safety of dexamethasone implants in subjects affected by diabetic macular edema（DME） resistant to anti-vascular endothelial growth factor（VEGF） therapy.METHODS： Thirty-two DME patients were enrolled.A700 microgram slow release Intravitreal Dexamethasone Implant（Ozurdex~） was placed in the vitreous cavity.All patients were followed for 18 mo.Best-corrected visual acuity（BCVA） measured with Early Treatment Diabetic Retinopathy Study（ETDRS） and central macular thickness（CMT） exams were carried out at baseline（T0）and after 1（T1）,3（T3）,4（T4）,6（T6）,9（T9）,12（T12）,15（T15）,and 18mo（T18） post injection. RESULTS： Repeated measures ANOVA showed an effect of treatment on ETDRS（P〈0.0001）.Post hoc analyses revealed that ETDRS values were significantly increased at T1,T3,T4,T9,and T15（P 〈0.001） as compared to baseline value（T0）.At T6,T12,and T18,ETDRS values were still statistically higher than baseline（P〈0.001 vs T0）.However,at these time points,we observed a trend to return to baseline conditions.ANOVA also showed an effect of treatment（P 〈0.0001）.CMT decreased significantly at T1,T3,T4,T9,and T15（P〈0.001）.At T6（P〈0.01）,T12 and T18（P〈0.001） CMT was also significantly lower than T0 although a trend to return to the baseline conditions was also observed.CONCLUSION： Our findings demonstrate that Intravitreal Dexamethasone Implant is a good option to improveBCVA and CMT in DME patients resistant to anti-VEGF therapy.Our data also show that the use of drugs administered directly into the vitreous allows achieving appropriate and long-lasting concentration at the site of disease without systemic side effects.

Comparison of topical nepafenac 0.1% with intravitreal dexamethasone implant for the treatment of Irvine-Gass syndrome

AIM: To compare safety and efficacy of intravitreal dexamethasone(IVD) implant with topical nepafenac(TN) 0.1% in previously untreated Irvine-Gass syndrome(IGS) in clinical practice. METHODS: This was a retrospective study of 62 eyes with IGS after phacoemulsification with posterior chamber intraocular lens(IOL) implantation. None of the patients used treatment before IVD or TN. Best-corrected visual acuity(BCVA) with Early Treatment Diabetic Retinopathy Study chart(ETDRS), slit-lamp, intraocular pressure(IOP) measurement, fundus examination, spectral-domain optical coherence tomography(OCT) and fundus florescein angiography were performed to all subjects at baseline, 1, 3 and 6 mo. RESULTS: The mean BCVA of the IVD group was 49.3±6.8, and the mean BCVA of the TN group was 32.9±7.3 ETDRS letters in post-treatment month 6. The mean central macular thickness(CRT) of IVD group was 266.6±53.5 μm and the mean CRT of TN group was 364.9±56.3 μm in posttreatment month 6. Baseline BCVA has correlation with final BCVA in TN group however there was no correlation between baseline BCVA and final BCVA in IVD group. CONCLUSION: IVD is found to be better than TN in controlling pseudophakic macular edema and improving visual acuity. IVD group also has significantly lower CRT however IOP is not significantly different between two groups in post-treatment month 6.

Combined Descemet stripping automated endothelial keratoplasty and intravitreal dexamethasone implant for concomitant pseudophakic bullous keratopathy and cystoid macular edema

Dear Editor,Endothelial cell density decreases with age and in various ocular conditions,including corneal endotheliitis,uveitis,pseudoexfoliation syndrome,and birth injury(1)The reduction of endothelial cell density is exacerbated over time after intraocular surgery(1)Descemet stripping automated endothelial keratoplasty(DSAEK)is considered the primary procedure for patients with only endothelial dysfunction.

Utilizing dexamethasone intravitreal implant to control postoperative inflammation in refractory uveitis undergoing cataract surgery

AIM:To report the effectiveness of intravitreal implantation of dexamethasone implant(Ozurdex)after phacoemulsification and intraocular lens implantation in refractory uveitis patients.METHODS:This single-center retrospective study conducted for refractory pan-uveitis patients who underwent cataract surgery combined with intravitreal Ozurdex implantation.The main outcome measurements were bestcorrected visual acuity(BCVA),central retinal thickness(CRT),grade of anterior chamber cell(AAC),intraocular pressure(IOP),and systemic/ocular adverse events.RESULTS:Ten eyes of 7 patients were included.BCVA showed significant improvement at 1 mo(P=0.004),3 mo(P=0.0004),and 6 mo(P=0.001)post operation.There were no statistically significant differences in the postoperative CRT among follow-up groups(P>0.05).No significant differences were observed in the baseline IOP when compared to 1,3,and 6 mo(all P>0.05)post operation.One patient developed a transient elevated IOP post injection.Two eyes(20%)developed posterior capsular opacifications and underwent neodymium-doped yttrium aluminum garnet(Nd:YAG)laser capsulotomy.In six patients(8 eyes,71.4%),the systemic steroid usage was reduced to below 10 mg/d.The patients experienced a mean of 1.4±0.52 recurrences of inflammation in the 6 mo before operation and 0.7±0.48 in the 6 mon post operation.The mean recurrence time was 13±0.58 wk(range 12-14 wk)post operation.In five of seven patients(7 out of 10 eyes),inflammation relapse was developed postoperatively.Only one patient(2 eyes)needed increased amounts of oral corticosteroids.Intraocular inflammation recurrence in the remaining patients was controlled by topical steroids.CONCLUSION:Ozurdex is considered a safe and effective approach to control postoperative inflammation in cataract surgery for patients with refractory uveitis in our study.After the disappearance of Ozurdex’s antiinflammatory effects over time,in most cases the recurrent inflammation can be controlled by topical steroids.

Dexamethasone intravitreal implant(Ozurdex) in diabetic macular edema: real-world data versus clinical trials outcomes

AIM: To investigate the safety and efficacy of intravitreal dexamethasone implants(Ozurdex?/DEX) in patients with diabetic macular edema(DME) either na?ve or nonna?ve to anti-VEGF therapies who switched to DEX implant independent of response to anti-vascular endothelial growth factors(anti-VEGFs).METHODS: This was an audit retrospective review of medical records of patients with DME who switched to the DEX intravitreal implant. Patients were divided into 2 groups: patients na?ve to antiangiogenic therapy and patients who were previously treated with anti-VEGFs. Data regarding demographics, changes in mean best-corrected visual acuity(BCVA), central macular thickness(CMT), and intraocular pressure(IOP) was collected over 6 mo. The demographic data mean changes in BCVA, CMT, and IOP were compared. Six-month follow-up data of 47 patients(57 eyes), who either switched to DEX implant irrespective of response to previous treatments or were treatment na?ve before receiving DEX implant, was collected.RESULTS: Improvement in mean BCVA was observed from 1-4 mo after injection with a decreased effect at month 6 as expected, with better outcomes in na?ve compared to non-na?ve patients. A statistically relevant decrease in mean CMT was observed during the follow-up period. An increase in mean IOP was observed in the first 2 mo after DEX therapy. The mean number of injections of the overall population during the 6 mo was 1.3. A subgroup analysis showed no relevant difference between phakic versus pseudophakic patients relative to measured outcomes. There was no cataract progression during the follow-up period and no adverse events reported.CONCLUSION: This real-life setting study shows that intravitreal DEX implant is effective and safe. The timings of greater therapeutic impact are concordant with previous studies and suggest that earlier treatment with corticosteroids may have an additional benefit in na?ve patients.

Combination of cataract surgery with intravitreal injection of dexamethasone intravitreal implant(Ozurdex)for uveitis-induced cataract

AIM:To evaluate the long-term results of patients with chronic uveitis-induced cataract by phacoemulsification with IOL implantation and intravitreal injection of dexamethasone(DEX)intravitreal implant(Ozurdex).METHODS:The study included 32 eyes of 26 patients treated with DEX implant due to chronic uveitis-induced cataract and followed up for at least a year.Best-corrected visual acuity(BCVA),intraocular pressure(IOP),anterior chamber reaction,central macular thickness(CMT),intraoperative and postoperative complications and uveitis recurrence were analyzed retrospectively.RESULTS:A successful surgery was performed in all patients.The average follow-up period was 12mo.The female/male ratio was 13/13.Mean age was 45.65±3.83y(range 26 to 65y).Etiologically,rheumatic arthritis occurred in 6 patients(18.75%),ankylosing spondylitis in 4(12.50%),HLA-B27 associated uveitis in 3(9.38%),Vogt-KoyanagiHarada-associated uveitis in 4(12.50%),Behcet’s disease in 2(6.25%),and 7(21.88%)suffered from unknown diseases.All 32 eyes had varying degrees of improvement at 12mo after surgery,with 2 eyes showing BCVA of 0.1 or below(6.25%),6 having 0.1-0.5(18.75%),18 of 0.5-1.0(56.25%),and 6 of 1.0 or above(18.75%).No cases with increased IOP were observed.The values of mean CMT was increased at day 1,decreased at 1,3mo after surgery and increased at 6,12mo after surgery.No severe uveitis reactions,such as fibrinous exudates in the anterior chamber and exudative membrane formation on the anterior surface of the IOL,were observed after surgery.CONCLUSION:The present studies show that intravitreal injection of Ozudex during cataract operation can provide a new option for the clinical treatment of uveitis-induced cataract.

Dexamethasone intravitreal implant for diabetic macular edema in a pregnant patient

Dear Editor,We present a case of dexamethasone（DEX）intravitreal implantation（Ozurdex~;Allergan,Irvine,CA,USA）to treat diabetic macular edema（DME）during pregnancy.According to Pescosolido et al,pregnancy may promote the onset of diabetic retinopathy in about 10%of cases and may contribute to its worsening when already present,causing macular edema.Although one report has indicated that DME during pregnancy spontaneously regresses after delivery,others have reported that DME can persist and be associated with severe and persistent visual dysfunction.

Retinal injury following intravitreal injection of a dexamethasone implant in a vitrectomized eye

Lee SM, Jung JW, Park SW, Lee JE, Byon IS. Retinal injury following intravitreal injection of a dexamethasone implant in a vitrectomized eye. Int J Ophthalmo12017; 10（6）： 1019-1020

Anatomical and functional changes after dexamethasone implant and ranibizumab in diabetic macular edema: a retrospective cohort study

AIM: To investigate the efficacy and safety of ranibizumab(RZB group) and dexamethasone implant(DEX group) intravitreal treatments in patients with treatment-na?ve center involved diabetic macular edema(DME) by means of functional and morphological assessments.METHODS: This retrospective cohort study included 50 eyes of 50 patients with DME treated either with RBZ or DEX. Best-corrected visual acuity(BCVA) and microperimetry were evaluated at baseline and during a 6-month follow-up. In addition, central macular thickness(CMT) by means of structural optical coherence tomography(OCT) and retinal capillary plexus density and choriocapillary density by means of OCT angiography were assessed in all cases.RESULTS: Functional and morphological parameters significantly improved during the study period in both groups. BCVA improved significantly in both groups witha greater increase in the DEX group compared to the RBZ group(P=0.030). Microperimetry significantly differed during follow-up between the two treatments(P=0.031). In both groups CMT significantly decreased(P<0.001) without statistically significant differences between the two groups. A statistically significant increase of deep capillary plexus density was detected in both groups at 30 d after therapy. The retreatment rate was 0.70±0.10 and 0.65±0.10 in the RBZ group and 0.65±0.10 and 0.50±0.11 in DEX group at 120 and 180 d respectively. Two out of 25 patients in DEX group showed intraocular pressure increase requiring hypotonic eye drops.CONCLUSION: Both treatments are very effective for DME treatment during 6 mo of follow-up with a lower retreatment rate in DEX group.

Posterior vitreous detachment rate following intravitreal dexamethasone injection

AIM: To determine whether intravitreal dexamethasone(DEX) implant induces posterior vitreous detachment or not. METHODS: We retrospectively reviewed 810 eyes of 405 patients who underwent intravitreal DEX implantation due to macular edema caused by diabetic and retinal venous occlusion in our clinic. The eyes having no injection were determined as the control group. The examination findings of the patients before the injection and 3 mo after the injection and optical coherence tomography(OCT) images were scanned. The pre-injection OCT findings and OCT findings of the patients having no posterior vitreous detachment(PVD) and determined to have partial PVD were compared. RESULTS: The separation in vitreoretinal adhesion and total PVD development of DEX-injected 56/208(26.9%) eyes were statistically greater in comparison with the 12/129(9.3%) eyes that had not been injected(P=0.001). PVD development was observed more in the patients that were younger, had larger macula thickness and lower visual acuity. CONCLUSION: It can be stated that intravitreal DEX implant induces PVD development. Prospective, controlled studies are required in order to determine prognosis of vitreoretinal disease in PVD-developed patients and in non-PVD-developed patients.

Complications of dexamethasone implants:risk factors,prevention,and clinical management

AIM:To evaluate major complications after intravitreal injection of dexamethasone implants(Ozurdex)and their clinical management.METHODS:In a retrospective observational study between 2014 and 2016 at two university hospitals,we reviewed the clinical records of 1241 consecutive macular edema patients treated with the dexamethasone implant,and separated severe adverse events in the injection procedure from those that were post-injection complications.We evaluated the cause and the outcomes in each case.RESULTS:In twenty-one procedures(1.69%)we noticed significant complications during and after intravitreal injection of the dexamethasone implant.Complications related to the injection procedure were in one case,that a second implant was injected by mistake in the same eye on the same day.In another case,the implant lodged in the sclera during retraction of the injector needle.Leaking scleral tunnel at the injection site led to hypotony in another case.There were 10 cases of post-injection displacement of the implant into the anterior chamber and one case with a migrated and trapped device between the intraocular lens and an artificial iris.Displacement typically occurred in patients with preexisting risk factors:eyes with complicated intraocular lens implantation,iris reconstruction or iris defects or pseudophakic eyes after vitrectomy were prone to develop this complication.Displacement led to secondary corneal decompensation with pseudohypopyon.One case developed an endophthalmitis,and we observed four cases of retinal detachment.Two eyes presented with long-lasting hypotony due to ciliary insufficiency.CONCLUSION:Treatment with the dexamethasone implant may cause various expected or unexpected complications that may have serious consequences for the patient and require further surgery.To reduce complications,clinicians should evaluate certain risk factors before scheduling patients for dexamethasone implant treatment and use proper injection techniques.

Optical Coherence Tomography (OCT) Feature Identifying Niche for Dexamethasone (FIND) Intravitreal Implant in the Treatment of Anti-VEGF Slow Responders with Diabetic Macular Edema

This paper raises the question if intravitreal dexamethasone implant deserves to be utilized more effectively in a select subset of eyes with diabetic macular edema (DME). If so, what is the OCT morphology of such eyes? A retrospective consecutive case series is employed to answer these questions. Twenty consecutive eyes were studied: ten that have been treated with intravitreal anti-VEGF (Group A) injections and ten which have been treated with the steroidal implant (Group O) because they failed or were slow to respond to multiple injections of anti-VEGF medications. Specifically, 1) macular edema in the eyes were categorized for the type of OCT morphology and 2) their response to the respective treatments in terms of the resolution of the OCT morphology was determined. Results show that the OCT morphology of eyes that were in Group O predominantly (7/10) had the feature of posterior retinal leakage (subretinal fluid and large outer retinal cysts);this feature was rare in Group A (2/10). Further, each of these eyes (7/7) in Group O had a complete resolution of the macular edema after a single treatment with the dexamethasone intravitreal implant whereas neither eye with this feature (0/2) responded to the (anti-VEGF) treatment in Group A. This leads to the conclusion that there exists an OCT Feature that Identifies a Niche for Dexamethasone Intravitreal implant (FIND) in the treatment of anti-VEGF slow responders in DME. The clinical significance of the study is that selecting eyes with a priori FIND morphology on the OCT for treatment with dexamethasone implant prior to, or at the outset of, a series of anti-VEGF treatment may resolve DME promptly and lower the treatment burden for patients and cost to society.

地塞米松玻璃体内植入剂移位至前房的研究进展

地塞米松玻璃体内植入剂(Ozurdex)不仅能治疗视网膜静脉阻塞继发的黄斑水肿、糖尿病性黄斑水肿和非感染性后葡萄膜炎,还能治疗内眼手术后黄斑水肿和其他炎症相关的眼底疾病继发的黄斑水肿。随着地塞米松玻璃体内植入剂广泛应用,不常见的并发症,如地塞米松玻璃体内植入剂移位至前房,逐渐受到重视。地塞米松玻璃体内植入剂移位至前房多见于悬韧带-晶状体囊膜复合体不完整、玻璃体切除术后的患眼。地塞米松玻璃体内植入剂移位至前房后多沉于下方房角,似前房积脓,可引起视力下降和眼痛,常并发角膜水肿和高眼压。合并角膜水肿的患眼应尽快复位或取出地塞米松玻璃体内植入剂,以降低角膜内皮失代偿风险。缩瞳和避免诱因,如俯卧、跳跃、长途飞行等,可以预防地塞米松玻璃体内植入剂移位至前房。文章主要综述了地塞米松玻璃体内植入剂移位至前房的研究进展,以期为地塞米松玻璃体内植入剂移位至前房的诊治和预防提供参考。

Ozurdex植入联合内界膜剥除治疗特发性黄斑前膜的效果观察

目的观察地塞米松玻璃体内植入剂(Ozurdex)植入联合内界膜(ILM)剥除术治疗特发性黄斑前膜(IEM)的有效性和安全性。方法回顾性分析2020年1月至2023年2月佛山市第二人民医院共21例(21眼)3~4期IEM患者均接受25G经睫状体平坦部玻璃体切除术(PPV)联合IEM及ILM剥除及Ozurdex植入术治疗的效果。主要观察指标为术后1、3、6、12个月时最佳矫正视力(BCVA)和黄斑视网膜厚度(CMT)。结果术后1、3、6、12个月患者BCVA均比术前改善,差异有统计学意义(P<0.05),分别较术前改善了0.30 logMAR、0.40 logMAR、0.40 logMAR、0.50 logMAR。术后1、3、6、12个月患者CMT均比术前组改善,差异有统计学意义(P<0.05),分别较术前下降了185.41、214.05、233.82、230.02μm。患者高眼压发生率为28.57%,PPV术后白内障手术率为46.15%,行白内障摘除术时间间隔为(6.50±1.40)个月。结论Ozurdex植入联合ILM剥除治疗IEM,可促进黄斑水肿消退、有效提高视力,但需注意白内障进展及高眼压症。

阿达木单抗联合地塞米松玻璃体腔植入剂治疗难治性非感染性葡萄膜炎性黄斑水肿

目的:探讨阿达木单抗联合地塞米松玻璃体腔植入剂治疗难治性非感染性葡萄膜炎性黄斑水肿(UME)的效果。方法:选取2020-01/2022-01我院收治的难治性非感染性UME患者92例131眼,随机分为对照组(46例63眼,接受地塞米松玻璃体腔植入剂治疗)和观察组(46例68眼,接受阿达木单抗皮下注射联合地塞米松玻璃体腔植入剂治疗)。分别于治疗前后检测最佳矫正视力(BCVA)、中心凹视网膜厚度(CRT)、玻璃体炎性混浊程度以及Th17/Treg细胞因子水平,记录不良反应发生情况。结果:纳入患者失访3例4眼。治疗1、3、6、12 mo,两组患者BCVA均较治疗前改善,CRT、玻璃体炎性混浊程度评分、血清白细胞介素(IL)-17、IL-22水平均较治疗前降低,血清转化生长因子-β(TGF-β)、IL-10水平均较治疗前升高,且观察组患者BCVA优于对照组,CRT、玻璃体炎性混浊程度评分、血清IL-17、IL-22水平均低于对照组,血清TGF-β、IL-10水平均高于对照组(均P<0.05)。治疗及随访期间,两组患者均未出现严重的不良反应。结论:阿达木单抗联合地塞米松玻璃体腔植入剂治疗难治性非感染性UME可显著促使黄斑水肿消退,减轻玻璃体炎性混浊,改善视力。

地塞米松玻璃体内植入物治疗眼部疾病的研究进展

随着全球人口老龄化趋势的加剧,眼部疾病的发病率显著增加,给公共卫生体系带来沉重负担。为应对这一日益严峻的视力健康挑战,开发新型治疗药物和方法已成为眼科学研究的核心课题。地塞米松玻璃体内植入物(DEX植入物)作为一种新兴的治疗手段,近年在糖尿病视网膜病变、视网膜静脉阻塞、葡萄膜炎等眼部疾病治疗中广泛应用。DEX植入物独特的药物递送系统能够在玻璃体腔内持续释放地塞米松,实现长效的抗炎和抗水肿作用。未来研究应进一步探讨DEX植入物在其他眼部疾病治疗中的潜力,并探索其与其他药物联合应用的可能性,以优化治疗效果和扩大适用范围。

地塞米松玻璃体内植入剂联合雷珠单抗治疗视网膜静脉阻塞继发黄斑水肿的临床效果

目的:探讨地塞米松玻璃体内植入剂(Ozurdex)联合雷珠单抗治疗视网膜静脉阻塞继发黄斑水肿(RVO-ME)疗效及对房水炎症因子的影响。方法:选择87例RVO-ME患者为研究对象,按不同治疗手段分为对照组(n=43,雷珠单抗治疗)与观察组(n=44,雷珠单抗+Ozurdex治疗)。比较两组最佳矫正视力(BCVA)、黄斑中央厚度(CMT)、眼压、房水炎性因子[单核细胞趋化蛋白1(MCP-1)、白细胞介素1β(IL-1β)及白细胞介素6(IL-6)]、视觉相关生活质量(CVRQoL-25评分)、药物注射次数、复发率及不良反应发生情况。结果:治疗后6个月,两组患者BCVA、CMT及眼压均较治疗前降低,且观察组更低(P<0.05);IL-1β、IL-6及MCP-1水平均较治疗前降低,且观察组更低(P<0.05);CVRQoL-25评分均较治疗前降低,且观察组CVRQoL-25评分及药物注射次数更低(P<0.05)。观察组不良反应总发生率、复发率分别为9.09%、40.91%;对照组分别为4.65%、51.16%,两组无统计学差异(P>0.05)。结论:Ozurdex联合雷珠单抗治疗RVO-ME可提高患者视力,缓解黄斑水肿,有助于减轻患者炎症反应、药物注射次数,提高患者视觉相关生活质量,且安全可靠。

地塞米松玻璃体内植入剂与雷珠单抗治疗视网膜静脉阻塞患者疗效及对MVD与FAZ的影响比较

目的 比较地塞米松玻璃体内植入剂与雷珠单抗治疗视网膜静脉阻塞(RVO)患者疗效及对黄斑区血流密度(MVD)与黄斑中心凹无血管区(FAZ)的影响。方法 选取2021年3月—2022年3月抚州爱尔眼科医院收治的RVO患者108例作为研究对象,以随机数字表法分为观察组和对照组,各54例。观察组予地塞米松玻璃体内植入治疗,对照组予雷珠单抗玻璃体内注射治疗。比较2组不同时点最佳矫正视力(BCVA)、黄斑中心凹厚度(CMT)、眼压,浅层毛细血管层(SCP)、深层毛细血管层(DCP)、脉络膜毛细血管层(CC)的MVD,FAZ面积及随访1年的复发情况。结果 治疗2周、1、3、6个月后,2组BCVA较治疗前升高,CMT较治疗前降低,且观察组治疗3、6个月后BCVA高于对照组,CMT低于对照组(P均<0.01);治疗2周、1、3、6个月后,对照组眼压与治疗前比较差异无统计学差异(P>0.05);治疗2周、1、3个月后,观察组眼压高于治疗前与同期对照组(P<0.05或P<0.01);2组治疗6个月后眼压比较无明显差异(P>0.05)。治疗前、治疗6个月后,2组SCP、DCP、CC层MVD及浅层与深层FAZ面积组内、组间比较差异均无统计学意义(P>0.05)。随访1年,观察组与对照组复发率(51.85%vs.55.56%)比较差异无统计学意义(χ^(2)=0.149,P=0.700)。观察组无复发持续时间为(6.75±0.43)月,长于对照组的(3.65±0.43)月(t=37.461,P<0.001)。结论 地塞米松玻璃体内植入剂与雷珠单抗治疗RVO均具有较佳疗效,地塞米松玻璃体内植入疗效持续时间较长,但治疗前期需密切监测眼压;2种治疗方法短期内对MVD、FAZ均无明显影响。

地塞米松联合康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿的临床研究

目的探讨地塞米松联合康柏西普治疗视网膜分支静脉阻塞(BRVO)继发黄斑水肿(ME)的临床疗效。方法选取2020年3月至2023年3月新余市人民医院收治的80例BRVO继发ME患者作为研究对象,采用随机信封法分为对照组(n=40)和研究组(n=40)。对照组接受玻璃体腔注射康柏西普治疗,在此基础上研究组加用玻璃体腔注射地塞米松。比较两组治疗前后最佳矫正视力(BCVA)、黄斑中心凹厚度(CMT),药物注射次数,药物不良反应发生率。结果两组患者治疗后1、3、6个月的CMT低于本组治疗前,差异有统计学意义(P<0.05)。两组患者治疗后1、3、6个月的BCVA低于本组治疗前,差异有统计学意义(P<0.05)。研究组平均注射次数低于对照组,差异有统计学意义(P<0.05)。两组药物不良反应总发生率比较,差异无统计学意义(P>0.05)。结论地塞米松与康柏西普联用是治疗BRVO继发ME有效且安全的方案,能有效减少黄斑水肿,促进视力恢复,且药物追加注射次数少。